Molecular docking and in silico ADMET studies of silibinin and glycyrrhetic acid anti-inflammatory activity by Malik, Arif et al.
Malik et al 
Trop J Pharm Res, January 2017; 16(1): 67 
 
Tropical Journal of Pharmaceutical Research January 2017; 16 (1): 67-74 
ISSN: 1596-5996 (print); 1596-9827 (electronic) 
© Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 300001 Nigeria.  
All rights reserved. 
 
Available online at http://www.tjpr.org 
http://dx.doi.org/10.4314/tjpr.v16i1.9 
Original Research Article 
 
 
Molecular docking and in silico ADMET studies of silibinin 
and glycyrrhetic acid anti-inflammatory activity 
 
Arif Malik1, Abdul Manan1 and Muhammad Usman Mirza2,3* 
1Institute of Molecular Biology and Biotechnology, 2Centre for Research in Molecular Medicine, The University of Lahore, 
Lahore, Pakistan, 3Department of Pharmaceutical and Pharmacological Sciences, Rega Institute for Medical Research, 
Medicinal Chemistry, University of Leuven, Leuven B-3000, Belgium 
 
*For correspondence: Email: usmanmirzapk@yahoo.com, muhammad.usman@imbb.uol.edu.pk 
 
Received: 21 July 2016     Revised accepted: 10 December 2016 
 
Abstract 
Purpose:To use in silico docking analysis and ADMET prediction of silibinin and glycyrrhetic acid to 
determine their pharmacokinetic and pharmacodynamic properties as therapeutic molecules against 
inflammatory disorders.  
Methods: The study utilized plant-derived compounds with known anti-inflammatory activity. Three 
important enzymes, including COX-2, 5β-reductase and phospholipase A2, that are involved in the 
mediation of inflammatory processes, were chosen as protein targets for the ligands (silibinin and 
glycyrrhetic acid). Q-Site Finder and admetSAR were employed for active site prediction and ADMET 
profile, respectively. Furthermore, protein-ligand complexes were visually inspected by LigPlot and 
Chimera. 
Results: Post-docking analysis confirmed strong interaction of silibinin and glycyrrhetic acid with their 
respective targets. ADMET profiles for both compounds were very promising. Both ligands (silibinin and 
glycyrrhetic acid) showed strong binding energy for all three target proteins (-7.5 to -10.9 kcal/mol). 
Moreover, Asp347, Gln350, Gly354, Gln192, His351, Ser579 and Phe580 were the common interacting 
residues in the target proteins for both ligands. 
Conclusion:Glycyrrhetic acid possesses superior ADMET profile to silibinin. Hydrophobic interactions 
between the two ligands (glycyrrhetinic acid and silibinin) and the three target proteins (COX-2, 
phospholipase A2 and 5β-reductase) are significant. 
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INTRODUCTION 
 
Xenobiotics and toxins injure the liver and can 
result in substantial hepatic pathology. The liver 
metabolizes and excretes drugs and xenobiotics. 
All drugs have some side effects, and many 
affect hepatocytes including cisplatin, tegafur, 
cyclophosphamide (anti-cancer drugs), 
nefazodone (an antidepressant), and some 
diabetes medications [1]. Hepatocytes are also 
responsible for the excretion of drugs from 
animals [1]. Drug overdose, toxins, 
chemotherapeutic agents like acetamide, and a 
hepatotoxic agent, carbon tetrachloride (CCl4) 
can damage hepatocytes and lead to liver 
inflammation (hepatitis) and cirrhosis [2]. Plants 
and their extracts have been usedto treat human 
diseases since ancient time. Among these, some 
plants have been reported to have additional 
medicinal value and beneficial characteristics 
including anti-inflammatory, immune-modulatory 
and anti-viral actions on hepatoprotective 
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properties [3-5]. The secondary metabolites of 
herbal treatments have become more prominent 
for the treatment of liver disease, with evidence-
based outcomes being established through 
promising clinical trials and validation. 
 
Silybummarianum, commonly known as milk 
thistle, produces seeds that have medicinal value 
when ripe [6,7]. Silymarin (SLN), an important 
secondary metabolite of Silybummarianum, 
consists of a complex mixture of four isomers 
(flavonolignans): silybin, isosilybin, silydianin, and 
silychristin. SLN has anti-inflammatory, anti-lipid, 
immuno-modulatory, anti-oxidative, and 
hepatocyte-regenerating actions. However, it is 
not thought to be anti-viral [1,2].Glycyrrhizaglabra 
is a leguminous plant belonging to the 
Leguminosae family [8]. The root extract of 
Glycyrrhizaglabra contains various chemical 
compounds of medicinal value including saponin, 
triterpines, flavonoids, and other chemicals like 
sugars, coumarins, amino acids, choline, and 
tannins [4,9,10].Moreover, in Japan, glycyrrhetic 
acid GLN is used for the management of chronic 
hepatitis C [11]. Glycyrrhizin metabolism is 
important because its metabolites inhibit the 
production of aldosterone and suppress 5-β 
reductase commonly called hepatic 
pseudoaldosterone syndrome. There is an 
inhibition of phospholipase A2 activity which is 
important in various inflammatory processes. 
Glycyrrhizin has the ability to interfere with 
cyclooxygenase and prostaglandin production 
involved in the progression of inflammatory 
mechanisms in biological system [18]. 
 
In the current study, molecular docking strategy 
was performed to find out their respective binding 
energies along with the number of hydrogen 
bonds and other hydrophobic interactions. The 
study was further validated by the use of in silico 
ADMET prediction of both compounds (silibinin 
and glycyrrhetic acid) in order to check their 
pharmacokinetics and pharmacodynamics 
properties. These two compounds have already 
being tested as potent therapeutic compounds in 
various experimental trials. The compounds are 
being viewed as potent therapeutic molecules in 
the management of inflammatory disorders.  
 
EXPERIMENTAL 
 
Target proteins were docked with silibinin and 
glycyrrhetic acid using AutoDock 4.2 and binding 
energies were calculated.  
 
Structure retrieval 
 
The three dimensional crystal structures of the 
three target proteins were retrieved from the 
Protein Data Bank. Cyclooxygenase-2 (6COX) 
[12], 5-beta-reductase (3BV7) [13], and 
phospholipase A2 (2B03) [14] were taken as 
targets. The ligand molecules, glycyrrhetic acid 
(GLN) and silibinin (SLB) were retrieved from 
PubChem (https://pubchem.ncbi.nlm.nih.gov) 
and were refined using ACD ChemSketch 
(http://www.acdlabs.com/resources/freeware), a 
tool that offers functionalities such as structure 
refining, optimization, etc. 
 
Active site prediction 
 
The active sites of all the three target proteins 
were identified using Q-SiteFinder [15]. Q-
SiteFinder works by binding hydrophobic probes 
to the protein. It then finds the clusters of probes 
with most favorable binding region based on 
energy values. It ranks these clusters according 
to the sum of total binding energies for individual 
clusters in the order of likelihood of being a 
binding site. 
 
Various pharmacodynamic as well as 
pharmacokinetic parameters were considered 
including human intestinal absorption (HIA), 
Caco-2 permeability, aqueous solubility, blood-
brain barrier penetration, renal organic cation 
transportation, cytochrome P (CYP) inhibitory 
promiscuity, cytochrome P450 inhibition, AMES 
toxicity, fish toxicity, rat acute toxicity, 
Tetrahymenapyriformis toxicity, human ether-a-
go-go-related genes inhibition, mutagenic, 
tumorigenic and reproductive risks (Table 1). 
 
Docking studies 
 
Target proteins were docked with silibinin and 
glycyrrhetic acid using AutoDock 4.2. The free 
energy of binding between the ingredients of 
ligands and proteins were calculated. AutoDock 
4.2 uses charge-based desolvation force fields 
and well defined improved models of the 
unbound state. Docking analysis attempts to bind 
the ligand into the obtained binding sites of the 
target protein and produces the best docked 
conformations with minimal energy, as the 
output. Semi-flexible docking protocol was 
applied, wherein the target proteins were kept 
rigid while the phytochemical ligands were kept 
flexible for being docked upon. A 5A° grid was 
built surrounding the binding pocket. Grid maps 
dimensions were set as 60 × 60 × 60 points with 
spacing of 0.375A° to yield the receptor model 
that included atoms within 0.5A° of the grid 
center. All the other parameters were kept at 
default and Lamarckian Genetic Algorithm (LGA) 
was chosen to predict the best conformers. The 
protein - ligand complexes were viewed by 
LigPlot viewer (http://www.ebi.ac.uk/thornton-
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srv/software/LIGPLOT) and Chimera 
(http://www.cgl.ucsf.edu/chimera). 
 
Drug-likeness analysis 
 
Chosen compounds were subjected to further 
selection on the basis of Lipinski’s rule of five 
(Ro5) [16]. Lipinski’s screening was performed 
using Molinspiration server (http://www.molins 
piration.com/cgi-bin/properties) and physicoche-
mical properties of ligands were calculated. Drug 
scores were calculated using ORISIS property 
explorer (http://www.organic-chemistry.org/ 
prog/peo). 
 
Absorption, distribution, metabolism, 
elimination and toxicity (ADMET) studies 
 
The molecular structure of both ligands were 
submitted to ADMET-SAR server (http://lmmd. 
ecust.edu.cn:8000) to examine their drug 
likeliness and different pharmacokinetic and 
pharmacodynamic parameters including blood-
brain barrier penetration, human intestinal 
absorption, Caco-2 permeability, cytochrome 
P450 solubility, cytochrome P (CYP) inhibitory 
promiscuity, renal organic cation transportation, 
human ether-a-go-go related genes inhibition, rat 
acute toxicity, fish toxicity, Tetrahymena 
pyriformis toxicity and Ames toxicity.  
 
RESULTS 
 
Both ligands (silibinin and glycyrrhetic acid) have 
shown strong binding energy with all three target 
proteins (-7.5 to -10.9 Kcal/mol).The said 
compounds followed the Lipinski’s rule in Table 2 
of five without any violation with respect to 
molecular weight (≤ 500KDa), an octanol-water 
partition coefficient (log P ≤ 5), molecular 
refractivity (40 - 130), number of H-bond 
acceptors (≤ 10) and number of H-bond donors 
(≤ 5). Lipinski’s rule of five analyzes various 
physiochemical properties [16]. These includes 
Log P anoctanol water partition coefficient which 
should be greater than or equal to 5, number of 
H-bonds donors and acceptor ≤5 and ≤10 
respectively, molecular weight of greater than 
500 and a molecular refractivity in the range of 
40-130. The Lipinski’s screening is an essential 
filter that determines if a compound is suitable for 
drug designing. Upon docking, both silibinin and 
glycyrrheticacid (Figure 1) formed at least one 
hydrogen bonds with all three target proteins. 
Docking with cyclooxygenase-2 (6COX) 
hydrogen bonds formation were observed with 
Phe580 residue having bond length of 2.84Å 
(silibinin) and 3.09Å (glycyrrhetic acid) as shown 
in Figure 2. Additionally, Asp347, Gln350, 
Gly354, Gln192, His351, Ser579, Phe580 were 
found to be common interacting residues in the 
target proteins for both ligands. 
 
Significant numbers of hydrophobic interactions 
were observed between the two ligands and all 
three target proteins. When docked with 5-beta-
reductase (3BV7) Pro221, Lys273, Ile271, Gly24, 
Tyr26, Trp230, Val309, Ser225, Ser220 residues 
interacted with silibinin and glycyrrhetic acid in 
addition to a few other residues. Similarly, 
Phospholipase A2 (2B03) docking analysis 
revealed Leu41, Tyr111, Leu19, Phe106, Ile9, 
Met20, Asn23, Leu31, Gly30, Leu2 and Tyr69 as 
common amino acid residues responsible for 
scoring a high binding energy of -8.8 kcal/mol 
and -10.9 kcal/mol for silibinin and glycyrrhetic 
acid respectively (Figure 3). All docking results 
are summarized in Table 3. 
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Figure1: Molecular structures of silibinin and glycyrrhetic acid 
 
 
Figure2: Schematic diagram of binding modes of glycyrrhetic acid (in grey) and silibinin (in purple) 
with respective target proteins: cyclooxygenase-2 (A), 5-Beta reductase (B) and phospholipase A2 
(C). The conserved residues of each target protein are shown in red circle for both ligands. This figure 
was produced by using LigPlot 
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Figure 3: Molecular representation of target proteins with docked compounds. Conformation of glycyrrhetic acid 
(in pink) and silibinin (in blue) shown by sticks inside the binding pocket of cyclooxygenase-2 (A), 5-Beta 
reductase (B) and phospholipase A2 (C) shown in molecular surface representation in sky blue color 
 
       Table 2: Comparison of drug-likeness properties of silibinin and glycyrrhetic acid 
 
Drug-likeness properties Silibinin Glycyrrhetic acid 
Molecular weight 482.4345 470.6825 
LogP 2.3627 -5.36 
LogS -3.41 -5.78 
H-bond acceptors 10 4 
H-bond donors 5 2 
Rotatable bonds 4 1 
Heavy atoms 35 34 
Hydrogen atoms 22 46 
PSA 155.14 74.6 
RO5 violation 0 0 
Refractivity 120.5501 136.8536 
Drug-Likeness score 1.64 -2.36 
Drug score 0.64 0.2 
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Table3: Comparison of binding energies (ΔG), interacting residues, H-bonds and hydrophobic interactions 
 
Target protein (PDB code) Docking results Silibinin Glycyrrhetic acid 
Cyclooxygenase-2 (6COX) Binding energy ΔG -8.3 -8.9 
Interacting residues Glu346, Asp347, Lys358, Gln350, 
His356, Gly354,Gln192, 
His351,Ser579,Phe580, Asn581, 
Asp525 
Asp347, Gln350, 
Gly354, Gln192, 
His351,Ser579, Phe580, 
Ile564 
H-bonds 
1(Asp515 - 3.06Å) 1(Asp347 - 3.00Å) 
1(Phe580 - 2.84Å) 1(Phe580 - 3.09Å) 
1(Asp581 - 3.05Å) 
Hydrophobic 
Interactions 10 8 
5-Beta-reductase (3BV7) Binding energy ΔG -10.1 -7.5 
Interacting residues Pro221, Leu222, 
Lys273,Ile271,Gly24,Ser220,Val231, 
Asn227, Tyr26, Trp230, 
Val309,Ser225, Arg279, Thr224 
Pro221, Lys273, Ile271, 
Tyr58, Tyr219, Gly24, 
Ser220, Glu120, Val121, 
Trp314, Trp89, Leu311, 
Asn170,Trp230, Val309, 
Ser225, Tyr26 
H-Bonds 
1(Tyr26 - 2.98Å) 
1(Lys273 - 3.24Å) 1(Arg279 - 2.88Å) 1(Thr224 - 2.87Å) 
1(Ser220 - 3.22Å) 
Hydrophobic 
interactions 11 16 
Phospholipase A2 (2B03) Binding energy ΔG -8.8 -10.9 
Interacting residues Leu2,Arg6,Tyr69, Asp21, Asn23, 
Leu31, Gly30,Phe22, Tyr25,Leu41, 
Tyr111, Leu19,Ile13,Phe106, Ile9, 
Met20 
Leu2,Tyr69, 
Asp21,Asn23, Leu31, 
Gly30, Tyr25, Asn24, 
Cys29, Leu41, Tyr111, 
Leu19,Phe106, Ile9, 
Met20 
H-bonds 1(Leu19 - 2.72Å) 1(Leu31 - 3.21Å) 1(Asn23 - 2.80Å) 1(Asn24 - 2.98Å) 
Hydrophobic 
interactions 14 13 
 
DISCUSSION 
 
Plants secondary metabolites have medicinal 
values and show therapeutic potential like anti-
viral, anti-inflammatory and immune-modulatory 
effects. The interest of investigators has been 
moved towards herbs because they are used as 
functional foods and an important source for the 
preparation of drugs. Hence, herbal medicines 
have been used worldwide for the treatment of 
various diseases. Inflammation is protective 
response involving molecular mediators, immune 
cells and blood vessels. Phytochemicals like 
silymarin and glycyrrhizin in suitable 
combinations are used as drugs for patients with 
liver disorders as they possess hepatoprotective 
property against inflammation [11,17]. Docking 
methodology facilitates structure-based virtual 
database screening with the ability to achieve a 
cost effective and quick estimation of the affinity 
and binding mode of a ligand for drug target. In 
this study, glycyrrhetic acid and silibinin have 
been shown to possess significant anti-
inflammatory activity from ADMET prediction. 
Moreover, the difference between binding 
energies can be observed in Table 3. Both the 
ligands occupied the same location in the protein 
targets and shared common amino acid residues 
for the inhibition of proteins’ action in 
inflammation.  
 
Poor pharmacokinetics and toxicity in the 
biological system lead to failure in drug 
development. With the help of ADMET profile 
during the process of drug discovery one can 
removeincompatible compounds as well as 
exhibit significant role in reducing cost and efforts 
[19]. For a drug to be approved for use, tedious 
toxicological analysis are performed to ensure its 
safety upon ingestion. In silico ADMET analysis 
is a quick approach to find if a compound has 
acceptable pharmacokinetics and 
pharmacodynamics property. The toxicity risks 
and bioavailability of silibinin and glycyrrhetic 
acid were predicted based on their ADMET 
profile [20]. Further analysis exhibit CYP 
inhibitory promiscuity as silibinin inhibit two 
cytochromes including CYP450-2C9 and 
CYP450-3A4. 
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Table1: ADMET-predicted features of glycyrrhetic acid and silibinin 
 
Property Glycyrrhiticacid Silibinin 
Blood-brain barrier BBB+ BBB- 
Human intestinal absorption HIA+ HIA+ 
Caco-2 permeability Caco2+ Caco+ 
P-glycoprotein substrate Substrate Substrate 
Renal organic cation transporter Non-inhibitor Non-inhibitor 
CYP450 2C9 substrate Non-substrate Non-substrate 
CYP450 2D6 substrate Non-substrate Non-substrate 
CYP450 3A4 substrate Substrate Non-substrate 
CYP450 1A2 inhibitor Non-inhibitor Non-inhibitor 
CYP450 2C9 inhibitor Non-inhibitor Inhibitor 
CYP450 2D6 inhibitor Non-inhibitor Non-inhibitor 
CYP450 2C19 inhibitor Non-inhibitor Non-inhibitor 
CYP450 3A4 inhibitor Non-inhibitor Inhibitor 
CYP inhibitory promiscuity Low CYP inhibitory 
promiscuity 
High CYP inhibitory 
promiscuity 
AMES toxicity Non-AMES toxic Non-AMES toxic 
Carcinogens Non-carcinogens Non-carcinogens 
Fish ioxicity High FHMT High FHMT 
Tetrahymenapyriformis toxicity High TPT High TPT 
Honey bee ioxicity High HBT High HBT 
Biodegradation 
Not readily 
biodegradable 
Not readily 
biodegradable 
Acute oral toxicity III III 
Carcinogenicity (three-class) Not-required Not-required 
 
Depending upon the acute oral toxicity (ADMET 
prediction profile), compounds are categorized 
into four groups. Category I contains compounds 
with LD50 values less than or equal to 50 mg/kg. 
Category II contains compounds with LD50 values 
greater than 50 mg/kg but less than 500 mg/kg. 
Category III includes compounds with LD50 
values greater than 500 mg/kg but less than 
5000 mg/kg. Category IV consisted of 
compounds with LD50 values greater than 5000 
mg/kg. 
 
The role of cytochrome P450 enzymes is very 
important as they are responsible for the 
metabolism of drug in biological system and its 
clearance from the body. Inhibition of any isoform 
of CYP leads to the malfunctioning of drug 
metabolism and elevation of toxicity [21].  
 
After ADMET analysis of compounds under study 
it was observed that glycyrrhetic acid possesses 
better ADMET profile when compared to silibinin, 
because it can cross blood-brain barrier but not 
the silibinin, it is non-inhibitor for all CYP-
inhibitors while silibinin is inhibitor for two CYPs 
like CYP-2C9 and CYP-3A4. Moreover, 
glycyrrhetic acid presented low CYP inhibitory 
promiscuity as compared to silibinin (Table 1). 
Both compounds were non carcinogenic and 
showed no AMES toxicity. Both compounds were 
found to be fit for drug development. 
 
CONCLUSION 
 
Glycyrrhetic acid possesses better ADMET 
profile than silibinin. Furthermore, hydrophobic 
interactions were significantly high between two 
ligands (glycyrrhetic acid and silibinin) and three 
target proteins (COX-2, phospholipase A2 and 
5β-reductase). Ligand-receptor complex showed 
that strong hydrogen bonding and van der Waals 
interactions were formed indicating that these 
two phytochemicals are suitable options as anti-
inflammatory agents as well as can be 
considered safe for development into a 
commercial drug when compared to other drugs 
in terms of their relatively fewer side-effects. 
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